Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

177.45
+2.381.36%
Volume:36.14K
Turnover:6.42M
Market Cap:7.15B
PE:-64.80
High:179.99
Open:179.99
Low:176.50
Close:175.07
52wk High:200.00
52wk Low:64.80
Shares:40.27M
Float Shares:19.38M
Volume Ratio:0.76
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7382
EPS(LYR):-2.3141
ROE:-22.10%
ROA:-15.65%
PB:9.20
PE(LYR):-76.68

Loading ...

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 20

Belite Bio Q1 Adjusted EPS USD -0.34

THOMSON REUTERS
·
May 20

Belite Bio Q1 Pretax Profit USD -26.938 Million

THOMSON REUTERS
·
May 20

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 20

Belite Bio Says Swiss Regulator Granted Orphan Drug Status to Tinlarebant to Treat Eye Disease

MT Newswires Live
·
May 19

Belite Bio receives orphan drug status for tinlarebant in Switzerland

TIPRANKS
·
May 19

Belite Bio Inc - Swissmedic Grants Orphan Drug Status to Tinlarebant for Stargardt Disease

THOMSON REUTERS
·
May 19

Swissmedic grants Belite Bio tinlarebant orphan drug status for Stargardt disease

Reuters
·
May 19

Belite Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
May 18

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 18

Belite Bio to present Phase 3 DRAGON tinlarebant data at Retina China symposium

Reuters
·
May 15

Belite Bio Announces Oral Presentation at the 27TH Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

THOMSON REUTERS
·
May 15

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

GlobeNewswire
·
May 15

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 15

Belite Bio to webcast first-quarter results, business update

Reuters
·
May 14

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

GlobeNewswire
·
May 14

Belite Bio CSO Nathan L. Mata disposes 666 shares worth $102,274.53

Reuters
·
May 09

Belite Bio CSO Nathan L. Mata reports disposal of shares worth $153,957.36

Reuters
·
May 08

Belite Bio CSO Nathan L. Mata sells shares worth $155,707.57

Reuters
·
May 06

Belite Bio CSO Nathan L. Mata disposes of shares worth $156,299.79

Reuters
·
May 05